Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Crititech Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio is spread across 3 distinct art units and 3 distinct examiners, indicating a range of technical review. While the workload is distributed, there is a point of concentration with the busiest examiner, HIRAKIS, SOPHIA P, who is responsible for 2 pending actions. The remaining pending office actions are split among the 3 distinct examiners assigned to the portfolio.
The fact that 3 distinct art units are involved for 4 pending office actions suggests that the company's Biotechnology & Pharmaceuticals innovations are categorized into several different specialized groups. Practitioners should focus on the 2 pending actions assigned to HIRAKIS, SOPHIA P, as this examiner manages a higher volume than the other assigned staff. Navigating 3 distinct art units requires a strategy that accounts for the specific procedural nuances of each unit while addressing the individual requirements of the 3 distinct examiners assigned to the 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIRAKIS, SOPHIA P | 2 | 56.1% | +73.5% |
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042930 | NICLOSAMIDE PARTICLES AND USES THEREOF | TRAN, SUSAN T | 31d overdue |
| 19293697 | Cisplatin particles and uses thereof | HIRAKIS, SOPHIA P | 14d |
| 18556705 | CISPLATIN PARTICLES AND USES THEREOF | HIRAKIS, SOPHIA P | — |
| 18492232 | Cisplatin particles and uses thereof | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1616 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19293697 | Cisplatin particles and uses thereof | HIRAKIS, SOPHIA P | 1623 | §103Other | Final Rejection | 14d | Pending | Aug 07, 2025 |
| 18556705 | CISPLATIN PARTICLES AND USES THEREOF | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18492232 | Cisplatin particles and uses thereof | HAGHIGHATIAN, MINA | 1616 | §103§112DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18042930 | NICLOSAMIDE PARTICLES AND USES THEREOF | TRAN, SUSAN T | 1615 | §103 | Non-Final OA | 31d overdue | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial